Effectiveness of Complex Treatment of Patients with Chronic Heart Failure Taking into Account Immune System Condition
AbstractIn order to evaluate glutargin and imunofan efficiency the changes of clinical manifestations and parameters of cellular and humoral immunity, oxidation-reduction processes, metabolic intoxication depending on CHF stage were studied in 96 patients suffering from arterial hypertension with chronic heart failure (CHF). Secondary immunodeficiency, activation of lipid peroxidation and metabolic intoxication increasing with CHF stage developed in patients with FC III CHF at stage II A and FC IV at stage II B according to NYHA. The use of glutargin and imunofan in complex treatment of the patients with CHF improves the effectiveness of treatment, the cellular and humoral immunity indices, reduces secondary immunodeficiency and metabolic intoxication.
Voronkov LH. “Path” of patients with chronic heart failure: as long and comfortable as possible. Sertseva nedostatnist. 2014; 1: 7-10.
Zharynova VYu. Modern possibilities of endothelial protecting therapy optimization in patients with CHF. Sertseva nedostatnist. 2013; 3: 45-53.
Riabenko DV. Pharmacotherapy of chronic heart failure in the XXI century: achievements and questions. Sertseva nedostatnist. 2014; 2: 24-33.
Michael Mahler, Pier-Luigi Meroni, Xavier Bossuyt, Marvin J. Fritzler Mahler Michael Current Concepts and Future Directions for the Assessment of Autoantibodies to Cellular Antigens Referred to as Anti-Nuclear Antibodies. Journal of Immunology Research. 2014; 18.
Pitt B, Latini R, Maggioni AP, Solomon SD, Smith BA, Wright M, Prescott MF, McMurray JV, Pitt B. Neurohumoral effects of aliskiren in patients with symptomatic heart failure receiving a mineralocorticoid receptor antagonist: the Aliskiren Observation of Heart Failure Treatment study. European Journal of Heart Failure. 2011; 13: 755–764.
Sinagra E, Perricone G, Romano C, Cottone M. Heart failure and anti tumornecrosis factor-alpha in systemic chronic inflammatory diseases. Eur. J. Intern. Med. 2013 Jan 17.
Ueland T, Yndestad A, Dahl CP et al. TNF revisited: osteoprotegerin and TNF-related molecules in heart failure. Curr. Heart Fail. Rep. 2012; 9 (2): 92-100.
Copyright (c) 2015 N. G. Virstiuk, O. E. Cherkashyna
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).